Novel Druggable Target to Treat Bipolar Disease

6 million adults in US have BP
- severe mood swings
- 1 in 5 commits suicide
All available BP drugs: toxic, poor efficacy, or both
Current trials lack novel compounds, mainly drug combinations
OCR5570 target levels affected in bipolar
- Target structures + hits known
- Screenable/Structure-based drug design
- Animal models available for in vivo validation
Critical protein-protein Interactions Identified
Amenable to split renilla luminescence assay